Rep. Gilbert Ray Cisneros, Jr. Buys Shares of Pfizer Inc. (NYSE:PFE)

Posted by Patrick Bannon on Mar 12th, 2026

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on March 09th, the Representative disclosed that they had bought between $1,001 and $15,000 in Pfizer stock on February 10th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Thermon Group (NYSE:THR) on 3/2/2026.
Purchased $1,001 – $15,000 in shares of Federal Signal (NYSE:FSS) on 3/2/2026.
Purchased $1,001 – $15,000 in shares of Taiwan Semiconductor Manufacturing (NYSE:TSM) on 2/26/2026.
Sold $1,001 – $15,000 in shares of Uber Technologies (NYSE:UBER) on 2/24/2026.
Sold $1,001 – $15,000 in shares of Robinhood Markets (NASDAQ:HOOD) on 2/24/2026.
Purchased $1,001 – $15,000 in shares of Micron Technology (NASDAQ:MU) on 2/24/2026.
Sold $1,001 – $15,000 in shares of Oracle (NYSE:ORCL) on 2/24/2026.
Purchased $1,001 – $15,000 in shares of Champion Homes (NYSE:SKY) on 2/23/2026.
Sold $1,001 – $15,000 in shares of Tri Pointe Homes (NYSE:TPH) on 2/23/2026.
Sold $1,001 – $15,000 in shares of Xiaomi (OTCMKTS:XIACF) on 2/20/2026.

Pfizer Price Performance

Shares of NYSE PFE traded down $0.46 during midday trading on Thursday, reaching $26.85. 38,500,025 shares of the company were exchanged, compared to its average volume of 37,183,588. The stock’s 50-day moving average price is $26.47 and its 200-day moving average price is $25.51. The stock has a market cap of $152.65 billion, a P/E ratio of 19.74 and a beta of 0.47. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.94.

Pfizer (NYSE:PFE – Get Free Report) last issued its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The business had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. During the same quarter last year, the business earned $0.63 EPS. The firm’s quarterly revenue was down 1.2% on a year-over-year basis. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, March 6th. Investors of record on Friday, January 23rd were issued a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.4%. Pfizer’s payout ratio is 126.47%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PFE. Triad Wealth Partners LLC raised its position in shares of Pfizer by 1.9% in the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock valued at $510,000 after purchasing an additional 386 shares during the period. ETF Store Inc. grew its stake in Pfizer by 3.8% in the 4th quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock valued at $272,000 after buying an additional 396 shares in the last quarter. Mattern Wealth Management LLC raised its holdings in Pfizer by 4.6% during the 4th quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock valued at $228,000 after acquiring an additional 400 shares during the period. Pines Wealth Management LLC lifted its position in shares of Pfizer by 4.4% during the fourth quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company’s stock worth $235,000 after acquiring an additional 400 shares in the last quarter. Finally, Peak Asset Management LLC lifted its position in shares of Pfizer by 1.4% during the second quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock worth $697,000 after acquiring an additional 402 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: China approved Pfizer’s GLP‑1 weight management drug Xianweiying for long‑term weight management in adults — opens a large new market and adds a growth vector vs. GLP‑1 competitors. Pfizer’s Weight Management Drug Wins China Approval
Positive Sentiment: Tilrekimig (trispecific antibody) reported encouraging Phase 2 eczema results — if confirmed in later‑stage trials this could meaningfully boost Pfizer’s immunology franchise and long‑term growth profile. How Tilrekimig’s Trispecific Eczema Data At Pfizer (PFE) Has Changed Its Investment Story
Positive Sentiment: Pfizer advanced an early‑stage oncology candidate (PF‑07994525), adding to the company’s cancer pipeline and optionality. Early trials expand long‑term R&D upside. Pfizer Advances Early-Stage Cancer Candidate PF-07994525, Extending Its Oncology Pipeline
Positive Sentiment: Completed Phase 2 toddler study for a next‑gen pneumococcal vaccine — progress here supports potential future vaccine launches and pediatric franchise strength. Pfizer Advances Next-Gen Pneumococcal Vaccine With Completed Phase 2 Toddler Study
Neutral Sentiment: Market/sector roundups and commentary mention Pfizer among peers but provide no immediate catalyst. Useful for context but unlikely to move the stock alone. Health Care Roundup: Market Talk
Neutral Sentiment: Executive commentary on navigating regulatory uncertainty highlights Pfizer’s regulatory expertise — background support but not an earnings driver. Be nimble, be ready: how to tackle regulatory uncertainty in clinical trials
Negative Sentiment: Coverage notes Pfizer has dipped more than the broader market, reflecting short‑term underperformance and investor caution. Pfizer (PFE) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Negative Sentiment: Analyses questioning Pfizer’s valuation and post‑pandemic growth (patent cliffs, pipeline risks) continue to pressure sentiment — these narratives can cap multiple expansion until clearer revenue drivers emerge. Pfizer: Cheap For A Reason
Negative Sentiment: Valuation/longer‑term value debates persist in recent pieces weighing pandemic sales declines and patent concerns against future pipeline gains. Does Pfizer (PFE) Offer Value After Post Pandemic Pipeline And Patent Concerns

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. TD Cowen reaffirmed a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. Scotiabank started coverage on shares of Pfizer in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 target price on the stock. Argus raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target for the company in a research note on Monday, March 2nd. Barclays began coverage on Pfizer in a research note on Thursday, February 19th. They issued an “underweight” rating and a $25.00 target price for the company. Finally, Morgan Stanley dropped their price target on Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Friday, December 12th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, fourteen have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and an average price target of $28.05.

Read Our Latest Stock Analysis on Pfizer

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Pfizer Company Profile

(Get Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.